Global Hodgkin’s Lymphoma
Treatment Market Regional Analysis
North America is expected to hold
a dominant position in the global Hodgkin’s
Lymphoma Market over the forecast period. Frequent research and development
activities done by the government and other organizations is expected to drive
the North America Hodgkin’s lymphoma treatment market growth. For instance, in
December 2016, Ohio State University Comprehensive Cancer Center and National
Cancer Institute (NCI) commenced a U.S. FDA clinical trial of Ibrutinib in
combination with Nivolumab, in the patients suffering from classical Hodgkin’s
Lymphoma, in the U.S to study its efficacy. Ibritunib may block the cancer cell
growth by blocking the enzymes responsible for growth and Nivolumab may block
cancer cells by targeting different cells. Currently, it’s in the second phase
of clinical trials. The study involves 17 participants and is estimated to be
completed by 2020.
Furthermore, various outside
organizations are involved in research and development activities for
development and gaining the U.S. FDA approval of novel Hodgkin’s lymphoma
treatment drug in the U.S.
Lymphoma is a cancer caused in
lymphocytes of the body, i.e. white blood cells. It is of two types – Hodgkin’s
Lymphoma and Non-Hodgkin’s Lymphoma. Hodgkin’s Lymphoma can be characterized
into two categories – classic and nodular lymphocyte predominant. Some of the
signs indicating presence of Hodgkin’s Lymphoma in the body is fever, sudden
weight loss, and swollen lymph nodes. Hodgkin’s Lymphoma is mostly treated with
chemotherapy alone or with the combination of radiotherapy.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2658
Global Hodgkin’s Lymphoma
Treatment Market Drivers
Approvals of the drugs by
regulatory bodies for the treatment of Hodgkin’s lymphoma is expected to drive
the global Hodgkin’s lymphoma market growth. In 2018, Seattle Genetics, Inc.
received the Health Canada approval for its supplemental New Drug Submission
that expands the use of Adcetris (brentuximab vedotin) in combination with AVD
(Adriamycin, vinblastine and dacarbazine) chemotherapy in patients with
previously untreated Stage IV Hodgkin lymphoma (HL). Adcetris is indicated for
the treatment of adult patients with previously untreated Stage III or IV
classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine,
and dacarbazine.
Furthermore, key players are
constantly trying to expand the indications of their already approved drug. For
instance, in March 2017, Merck & Co. Inc. received an approval by U.S. Food
& Drug Administration (FDA) of the drug, Keytruda for the treatment of
classical Hodgkin’s lymphoma. It is approved on the basis of response durability
and tumor response rate and is supposed to be administered intravenously into
patients. It was originally approved in 2014. Such frequent approvals of drugs
by regulatory bodies are expected to impact positively on the global Hodgkin’s
lymphoma treatment market growth.
For instance, in September 2017,
Chinese PLA General Hospital, a Chinese government organization, commenced its
clinical trial of Decitabine in combination with SHR – 1210. It is being used
for the treatment of Hodgkin’s lymphoma. SHR – 1210 is a monoclonal antibody,
while Decitabine is an investigational drug, which is capable of boosting
antigen expression. The clinical study is for analyzing the safety and efficacy
of the drugs. Currently, it is in the second phase of clinical trials.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/hodgkins-lymphoma-treatment-market-2658
Global Hodgkin’s Lymphoma
Treatment Market Restraints
Side effects related with drugs
used for the treatment of Hodgkin’s lymphoma is expected to adversely affect
adoption of these drugs, thereby hindering the global Hodgkin’s lymphoma
treatment market growth. For instance, according to American Cancer Society,
drugs used for treating Hodgkin’s lymphoma such as doxorubicin and bleomycin
can damage heart and lungs respectively. Hence, such side effects of drugs can
hinder the global Hodgkin’s lymphoma treatment market growth.
Global Hodgkin’s Lymphoma
Treatment Market Key Players
Some of the major players
operating in the global Hodgkin’s lymphoma treatment market include Emcure
Pharmaceuticals Pvt. Ltd., Aspen Global Inc., Pfizer Inc., Ono Pharmaceuticals
Co. Ltd., Corden Pharma Latina SPA, Horizon Pharma USA Inc., Cipla Ltd.,
Lediant Biosciences Inc., Jansenn Research and Development LLC, and Merck &
Co., Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2658
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to emerging
market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment